A private equity owned drugmaker is under investigation by the UK’s competition watchdog after its threats to withdraw one of its bipolar medicines triggered a fierce backlash from doctors over access and pricing, reported the Financial Times.
Essential Pharma, which was bought out by Swiss private equity firm Gyrus Capital in January, planned to pull lithium-based medicine priadel from the market in April 2021, pushing thousands of patients with bipolar disorder towards the company’s more costly drug.
The company on Tuesday, October 6, stated it had failed to agree a “sustainable price” for lossmaking priadel with the Department of Health but would continue to supply the drug after the Competition and Markets Authority announced its probe.
At least one in a 100 people in the UK are diagnosed with bipolar disorder, and of those 20% take lithium tablets. Essential Pharma makes two of the three lithium carbonate medicines used to treat bipolar disorder in England.
Priadel costs £4.02 (US$5.18) for a pack of 100 400mg pills while the cost of Essential Pharma’s lithium-based alternative camcolit is £48.18(US$62.07). The company’s most expensive lithium carbonate tablet costs £87(US$112.08) for 100 250mg pills.
Featured News
EU Regulators Set to Clear Microsoft’s $13B OpenAI Investment
Apr 17, 2024 by
CPI
Biden Pledges to Block US Steel Acquisition by Japanese Firm
Apr 17, 2024 by
CPI
Canada Targets Tech Titans with New Digital Tax in 2024
Apr 17, 2024 by
CPI
EU Privacy Watchdog Calls for Meta to Offer Ad-Free Option
Apr 17, 2024 by
CPI
Japan’s Antitrust Overhaul Targets Tech Titans Like Apple
Apr 17, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – China Edition – Year of the Dragon
Apr 16, 2024 by
CPI
Review Logic and Rules for Concentrations of Undertakings that Do Not Meet the Standard of Notification
Apr 16, 2024 by
CPI
China’s Review of Semiconductor Transactions
Apr 16, 2024 by
CPI
Key Challenges and Tips for Merger Control Filing in China for Listed Companies
Apr 16, 2024 by
CPI
Key Point Review: China SPC Antitrust Judgments in 2023
Apr 16, 2024 by
CPI